FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3051707275> ?p ?o ?g. }

• W3051707275 endingPage "25" @default.
• W3051707275 startingPage "15" @default.
• W3051707275 abstract "Oral semaglutide is a tablet formulation of a glucagon-like peptide-1 receptor agonist (GLP-1RA), recently approved in the USA and other countries. This paper reviews data from clinical trials (PIONEER 1, 2, 3, and 7) comparing oral semaglutide (once-daily doses of 3, 7, or 14 mg) with either once-daily placebo, empagliflozin 25 mg, or sitagliptin 100 mg. After 26 weeks in PIONEER 1, patients randomized to 3, 7, or 14 mg doses of oral semaglutide monotherapy had statistically significant reductions in glycated hemoglobin (HbA1c) of 0.9%, 1.2%, and 1.4%, respectively, versus 0.3% with placebo. In the active-comparator studies, oral semaglutide 14 mg provided better glycemic control than empagliflozin or sitagliptin after 26 weeks, with durable effects. Body weight reductions were significantly greater with oral semaglutide than with placebo and sitagliptin. However, body weight reductions with oral semaglutide 14 mg versus empagliflozin 25 mg were not significantly different. Gastrointestinal adverse events (AEs) with oral semaglutide were mostly mild-to-moderate, occurred early in the course of treatment, and abated over time. Across these trials, 5–13% and 15–20% of patients experienced nausea with oral semaglutide 7 and 14 mg, respectively, and 2.3–3.4% and 5.1–8.0%, respectively, discontinued treatment due to gastrointestinal AEs. Severe or blood glucose-confirmed symptomatic hypoglycemia occurred infrequently with oral semaglutide and was seen most often in patients taking concomitant sulfonylureas. Findings from these trials indicate that the addition of oral semaglutide reduces HbA1c and body weight and is associated with a low risk of hypoglycemia. Oral semaglutide represents an additional option for treating people with type 2 diabetes in primary care, with the potential to expand the numbers of patients benefiting from GLP-1RAs beyond that currently seen with injectable formulations." @default.
• W3051707275 created "2020-08-24" @default.
• W3051707275 creator A5020370542 @default.
• W3051707275 creator A5070289715 @default.
• W3051707275 date "2020-09-08" @default.
• W3051707275 modified "2023-09-24" @default.
• W3051707275 title "Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo" @default.
• W3051707275 cites W2009830637 @default.
• W3051707275 cites W2010400528 @default.
• W3051707275 cites W2058407858 @default.
• W3051707275 cites W2138480916 @default.
• W3051707275 cites W2146264128 @default.
• W3051707275 cites W2159205789 @default.
• W3051707275 cites W2425644022 @default.
• W3051707275 cites W2519510391 @default.
• W3051707275 cites W2550011910 @default.
• W3051707275 cites W2626446274 @default.
• W3051707275 cites W2743088090 @default.
• W3051707275 cites W2745170751 @default.
• W3051707275 cites W2754588358 @default.
• W3051707275 cites W2765781150 @default.
• W3051707275 cites W2773969925 @default.
• W3051707275 cites W2883028824 @default.
• W3051707275 cites W2894746763 @default.
• W3051707275 cites W2909960874 @default.
• W3051707275 cites W2922550132 @default.
• W3051707275 cites W2948380809 @default.
• W3051707275 cites W2948612418 @default.
• W3051707275 cites W2951522032 @default.
• W3051707275 cites W2953860251 @default.
• W3051707275 cites W2974621372 @default.
• W3051707275 cites W2990539453 @default.
• W3051707275 cites W3004838676 @default.
• W3051707275 cites W3006729360 @default.
• W3051707275 cites W3007606426 @default.
• W3051707275 cites W3080218024 @default.
• W3051707275 cites W3080787886 @default.
• W3051707275 cites W3081124857 @default.
• W3051707275 cites W3081499157 @default.
• W3051707275 cites W3155428796 @default.
• W3051707275 cites W4246340431 @default.
• W3051707275 cites W4256659255 @default.
• W3051707275 cites W984807221 @default.
• W3051707275 doi "https://doi.org/10.1080/00325481.2020.1798638" @default.
• W3051707275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32815436" @default.
• W3051707275 hasPublicationYear "2020" @default.
• W3051707275 type Work @default.
• W3051707275 sameAs 3051707275 @default.
• W3051707275 citedByCount "7" @default.
• W3051707275 countsByYear W30517072752020 @default.
• W3051707275 countsByYear W30517072752021 @default.
• W3051707275 countsByYear W30517072752022 @default.
• W3051707275 countsByYear W30517072752023 @default.
• W3051707275 crossrefType "journal-article" @default.
• W3051707275 hasAuthorship W3051707275A5020370542 @default.
• W3051707275 hasAuthorship W3051707275A5070289715 @default.
• W3051707275 hasBestOaLocation W30517072751 @default.
• W3051707275 hasConcept C126322002 @default.
• W3051707275 hasConcept C134018914 @default.
• W3051707275 hasConcept C142724271 @default.
• W3051707275 hasConcept C197934379 @default.
• W3051707275 hasConcept C204787440 @default.
• W3051707275 hasConcept C27081682 @default.
• W3051707275 hasConcept C2775887513 @default.
• W3051707275 hasConcept C2777180221 @default.
• W3051707275 hasConcept C2777538456 @default.
• W3051707275 hasConcept C2779284873 @default.
• W3051707275 hasConcept C2779306644 @default.
• W3051707275 hasConcept C2779829264 @default.
• W3051707275 hasConcept C2780533449 @default.
• W3051707275 hasConcept C2780668416 @default.
• W3051707275 hasConcept C2781308992 @default.
• W3051707275 hasConcept C2909862629 @default.
• W3051707275 hasConcept C555293320 @default.
• W3051707275 hasConcept C71924100 @default.
• W3051707275 hasConcept C90924648 @default.
• W3051707275 hasConcept C98274493 @default.
• W3051707275 hasConceptScore W3051707275C126322002 @default.
• W3051707275 hasConceptScore W3051707275C134018914 @default.
• W3051707275 hasConceptScore W3051707275C142724271 @default.
• W3051707275 hasConceptScore W3051707275C197934379 @default.
• W3051707275 hasConceptScore W3051707275C204787440 @default.
• W3051707275 hasConceptScore W3051707275C27081682 @default.
• W3051707275 hasConceptScore W3051707275C2775887513 @default.
• W3051707275 hasConceptScore W3051707275C2777180221 @default.
• W3051707275 hasConceptScore W3051707275C2777538456 @default.
• W3051707275 hasConceptScore W3051707275C2779284873 @default.
• W3051707275 hasConceptScore W3051707275C2779306644 @default.
• W3051707275 hasConceptScore W3051707275C2779829264 @default.
• W3051707275 hasConceptScore W3051707275C2780533449 @default.
• W3051707275 hasConceptScore W3051707275C2780668416 @default.
• W3051707275 hasConceptScore W3051707275C2781308992 @default.
• W3051707275 hasConceptScore W3051707275C2909862629 @default.
• W3051707275 hasConceptScore W3051707275C555293320 @default.
• W3051707275 hasConceptScore W3051707275C71924100 @default.
• W3051707275 hasConceptScore W3051707275C90924648 @default.
• W3051707275 hasConceptScore W3051707275C98274493 @default.
• W3051707275 hasIssue "sup2" @default.

• next